Théa Pharma Inc. provides Canadian eye care professionals and patients with  innovative solutions to a wide range of eye conditions

TORONTO , Jan. 10, 2023 /CNW/ – The successful completion of the five-year joint venture between two family-owned specialty eye care companies, Laboratoires Théa (“Théa”) based in France , and Canada’s Labtician Ophthalmics, has given rise to the newly minted Théa Pharma Incorporation (Théa Pharma Canada), with headquarters inside Toronto, Ontario .   Both organizations benefited from their collaboration over the last 5 years and are now well positioned in order to pursue their distinct specialties. With the goal of becoming Canada’s leading provider of preservative-free eye treatment solutions, Théa Pharma North america will devote 100 percent associated with its attention to eye care, and to the professionals who manage the particular eye health of Canadians across the country.

Théa Pharma Europe has plans to accelerate its growth and presence in Nova scotia by leveraging the culture and values of its family-owned plus run parent company, Théa, Europe’s leading and pioneering eye wellness brand founded in 1994 by Henri Chibret. In addition in order to bringing best-in-class eye treatment methods to Canadian patients, Théa Pharma Canada plans to embody the particular spirit of product innovation, professional education and strong partnerships that have been critical in order to Théa’s success globally. As an affiliate of a highly successful global entity, Théa Pharma Canada will leverage global reinvestment in R& D to introduce new and novel preservative-free treatments to the Canadian market, as well as provide access for Canadian eye care professionals in order to value-added schooling, training and other programs led by world experts in eye treatment.

The transaction, which became effective on January 1 st , 2023, is significant for the Company upon many levels. “Although our name will be new, what will not change is our own long-term commitment to Canadian ophthalmologists, optometrists, and their own patients, ” said Fiona McCloskey , General Manager, Théa Pharma Canada.   “Canadian eye care professionals have come to rely on us for the cutting-edge preservative-free treatments, but also see us as a valued partner in finding strategies to the wide range of ocular conditions including Dry Eye, Lid Margin Disease, Glaucoma, Allergy, and more. We look forward to continuing our partnership with the Canadian vision care community in 2023, and for many years to come, using the mission to protect and promote the attention health associated with all Canadians. ”

Enabling everyone to keep their eyes wide open to the globe, preserving eyesight and preventing eye disease is Théa Pharma Canada’s goal.   According to a Canadian Council of the Blind Report commissioned in collaboration with Fighting Blindness North america, the Canadian Association of Optometrists, plus the Canadian Ophthalmological Society, eight million Canadians, almost a quarter from the population, live with an eye disease that could result in vision loss and blindness. The good news is that early diagnosis plus treatment could help three-quarters of these individuals from losing their particular vision and going blind. i


Théa Pharma Canada  is an affiliate associated with Théa, Europe’s leading independent eye care group with a singular focus on the research, development, plus commercialization of eye treatment products. Based in Toronto, Ontario , Théa Pharma Canada’s current portfolio includes products for dry eye  (Thealoz Duo®, Thealoz Duo® Gel, Hyabak®, Thealoz™), lid hygiene (Blephaclean®, Blephagel® Duo), glaucoma (Monoprost®), and allergy (Zaditor®).

Théa Pharma Canada  has plans in order to launch several products over the next 12-18 months, including the recent Health Canada approved Eyezirgan® for that treatment associated with ocular herpes simplex keratitis, Zaspray® with regard to the treatment of dry eyesight associated along with allergy, Duokopt®, a combination product for your treatment of glaucoma, and other products within their lid hygiene variety.


Théa  is the leading independent European pharmaceutical group in ophthalmology. Based in Clermont-Ferrand, France , it offers thirty-five affiliates & offices in Europe , North and South America , North Africa , and the Middle East . Today, its network includes more than 1, 600 employees, and its products are available in 75 countries around the particular world. Within 2021, Théa had worldwide revenues of approximately $773 mil .   The impartial and family-owned and run group, started from a Research and Development start-up by Henri Chibret, has already been chaired since 2008 simply by Jean-Frédéric Chibret, his nephew.   To learn more about Théa, visit .

SOURCE Théa Pharma Inc.

For further information: Fiona McCloskey, General Supervisor, Théa Pharma Canada, Tel: 416-669-0585, [email protected] ; Media Contact: Claire Dawson, energi PR, Tel: 905-510-4127, [email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *